Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR8392892

· cohortA1

23a9b0c4-0b8e-558d-bdad-ab280e84c8c9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortA1
subtype
cohortA1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.300
  • PANCREAS_BETA_CELLS+0.290
  • ALLOGRAFT_REJECTION+0.280
  • INTERFERON_ALPHA_RESPONSE+0.270
  • INTERFERON_GAMMA_RESPONSE+0.140
  • SPERMATOGENESIS+0.140
  • MYOGENESIS+0.120
  • COAGULATION+0.080
  • INFLAMMATORY_RESPONSE-0.020
  • XENOBIOTIC_METABOLISM-0.040

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.560
  • WNT_BETA_CATENIN_SIGNALING-0.500
  • PROTEIN_SECRETION-0.480
  • UNFOLDED_PROTEIN_RESPONSE-0.470
  • MYC_TARGETS_V1-0.450
  • MTORC1_SIGNALING-0.430
  • MITOTIC_SPINDLE-0.410
  • TNFA_SIGNALING_VIA_NFKB-0.390
  • UV_RESPONSE_DN-0.390
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.370

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-49-AAR2-01A-11R-A39D-07
lung-landscapes@6
cohortA30.936
2TCGA-49-AARQ-01A-11R-A41B-07
lung-landscapes@6
cohortA10.918
3SRR33346946
bladder-landscape@3
0.913
4SRR8942994
bladder-landscape@3
0.904
5MDT-AP-1327
medullo-epn-umap@date-based
MedMedulloblastoma0.899
6SRR12202406
bladder-landscape@3
0.898
7SRR25617833
breast-umap@18
B0.891
8MNG499
mng-umap@100
0.887
9MNG763
mng-umap@100
0.882
10MNG599
mng-umap@100
0.880

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 8 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.300Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.290Cobimetinib— uncovered
ALLOGRAFT_REJECTION0.280Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.270Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.140Idelalisib— uncovered
SPERMATOGENESIS0.140Inavolisib— uncovered
MYOGENESIS0.120Inavolisib— uncovered
COAGULATION0.080Binimetinib— uncovered